Dyne Therapeutics, Inc. (DYN) 10-Year Financial Performance & Capital Metrics

DYN • • Industrial / General

HealthcareBiotechnologyRare Genetic DiseasesGene Therapy & Rare Diseases

AboutDyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts..Show more

Revenue $0
EBITDA -$342M -42.5%
Net Income -$317M -34.5%
EPS (Diluted) -3.37 +14.7%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -88.03% +35.9%
ROIC -239.41% +29.0%
Debt/Equity 0.04 -87.3%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Momentum leader: RS Rating 84 (top 16%)

✗Weaknesses

✗Shares diluted 57.7% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-43.9%

EPS CAGR

10Y-

5Y-

3Y-

TTM-2.81%

ROCE

10Y Avg-47.43%

5Y Avg-67.55%

3Y Avg-88.09%

Latest-90.14%

Peer Comparison

Gene Therapy & Rare Diseases

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
KRYSKrystal Biotech, Inc.	8.46B	291.79	97.26	473.02%	53.3%	17.48%	1.41%	0.01
BMRNBioMarin Pharmaceutical Inc.	10.77B	56.08	25.38	17.97%	16.82%	8.59%	4.41%	0.11
SRPTSarepta Therapeutics, Inc.	2.39B	22.80	9.74	52.97%	-11.25%	-20.57%		0.88
RAREUltragenyx Pharmaceutical Inc.	2.32B	24.07	-3.83	29.01%	-91.95%	-35.88%		0.15
DYNDyne Therapeutics, Inc.	2.87B	17.45	-5.18			-61.26%		0.04
TVTXTravere Therapeutics, Inc.	2.59B	28.93	-7.09	60.55%	-20.32%	-120.36%		6.80
BEAMBeam Therapeutics Inc.	3.59B	35.41	-7.73	-83.18%	-7.44%	-42.92%		0.22
SLNOSoleno Therapeutics, Inc.	2.28B	42.46	-9.69		-79.5%	-15.85%		0.22

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	842M	1.37B	506M	0	0	0	0	0	0	0
Revenue Growth %	-0.43%	0.62%	-0.63%	-1%	-	-	-	-	-	-
Cost of Goods Sold+	2.03B	2.28B	2.93B	24K	271K	700K	0	0	2.46M	2.24M
COGS % of Revenue	2.41%	1.67%	5.79%	-	-	-	-	-	-	-
Gross Profit+	-1.19B	-915M	-2.43B	-24K	-271K	-700K	0	0	-2.46M	-2.24M
Gross Margin %	-1.41%	-0.67%	-4.79%	-	-	-	-	-	-	-
Gross Profit Growth %	-4.69%	0.23%	-1.65%	1%	-10.29%	-1.58%	1%	-	-	0.09%
Operating Expenses+	128M	161M	189M	4.79M	13.83M	57.95M	150.03M	170.96M	239.7M	341.64M
OpEx % of Revenue	0.15%	0.12%	0.37%	-	-	-	-	-	-	-
Selling, General & Admin	128M	161M	189M	517K	2.79M	12.75M	28.72M	28.2M	31.4M	62.48M
SG&A % of Revenue	0.15%	0.12%	0.37%	-	-	-	-	-	-	-
Research & Development	0	0	0	4.28M	11.04M	45.2M	121.31M	142.76M	210.76M	281.41M
R&D % of Revenue	-	-	-	-	-	-	-	-	-	-
Other Operating Expenses	0	0	0	-21K	0	0	0	0	-2.46M	-2.24M
Operating Income+	64M	-640M	-412M	-4.79M	-13.83M	-58.65M	-150.03M	-170.96M	-242.16M	-343.89M
Operating Margin %	0.08%	-0.47%	-0.81%	-	-	-	-	-	-	-
Operating Income Growth %	1.2%	-11%	0.36%	0.99%	-1.88%	-3.24%	-1.56%	-0.14%	-0.42%	-0.42%
EBITDA+	678M	126M	455M	-4.77M	-13.55M	-57.95M	-148.94M	-169.28M	-239.7M	-341.64M
EBITDA Margin %	0.81%	0.09%	0.9%	-	-	-	-	-	-	-
EBITDA Growth %	27.08%	-0.81%	2.61%	-1.01%	-1.84%	-3.27%	-1.57%	-0.14%	-0.42%	-0.43%
D&A (Non-Cash Add-back)	614M	766M	867M	24K	271K	700K	1.09M	1.68M	2.46M	2.24M
EBIT	119M	-664M	78M	-4.81M	-14.86M	-59.04M	-150.03M	-170.96M	-235.94M	-317.42M
Net Interest Income+	0	0	0	0	290K	-340K	742K	0	7.64M	26.92M
Interest Income	0	0	0	5K	290K	56K	742K	2.92M	7.64M	26.92M
Interest Expense	546M	625M	616M	5K	0	396K	0	2.92M	0	0
Other Income/Expense	-491M	-649M	-126M	-16K	-1.03M	-790K	734K	2.86M	6.22M	26.47M
Pretax Income+	-427M	-1.29B	-538M	-4.81M	-14.86M	-59.44M	-149.29M	-168.1M	-235.94M	-317.42M
Pretax Margin %	-0.51%	-0.94%	-1.06%	-	-	-	-	-	-	-
Income Tax+	-474M	-45M	-610M	-11K	0	-700K	0	0	0	0
Effective Tax Rate %	-0.12%	0.96%	-0.14%	1%	0.91%	0.99%	1%	1%	1%	1%
Net Income+	50M	-1.24B	76M	-4.81M	-13.54M	-58.74M	-149.29M	-168.1M	-235.94M	-317.42M
Net Margin %	0.06%	-0.91%	0.15%	-	-	-	-	-	-	-
Net Income Growth %	1.75%	-25.8%	1.06%	-1.06%	-1.81%	-3.34%	-1.54%	-0.13%	-0.4%	-0.35%
Net Income (Continuing)	50M	-1.24B	76M	-4.81M	-14.86M	-58.74M	-149.29M	-168.1M	-235.94M	-317.42M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	0.40	-9.61	0.47	-0.47	-0.30	-1.24	-2.93	-3.23	-3.95	-3.37
EPS Growth %	1.75%	-25.02%	1.05%	-2%	0.36%	-3.13%	-1.36%	-0.1%	-0.22%	0.15%
EPS (Basic)	0.40	-9.61	0.47	-0.47	-0.30	-1.24	-2.93	-3.23	-3.95	-3.37
Diluted Shares Outstanding	126M	129M	162M	10.32M	45.42M	47.27M	50.9M	51.98M	59.68M	94.14M
Basic Shares Outstanding	125M	129M	162M	10.32M	45.42M	47.27M	50.9M	51.98M	59.68M	94.14M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	1.95B	2.99B	1.52B	8.16M	14.76M	349.09M	382.39M	265.59M	129.38M	659.28M
Cash & Short-Term Investments	605M	1.91B	397M	8.12M	14.63M	345.31M	376.57M	256.01M	123.1M	642.27M
Cash Only	505M	1.78B	365M	8.12M	14.63M	300.85M	200.82M	172.15M	121.63M	435.45M
Short-Term Investments	100M	130M	32M	0	0	44.46M	175.75M	83.86M	1.47M	206.82M
Accounts Receivable	402M	386M	513M	0	0	0	0	0	0	0
Days Sales Outstanding	174.26	103.14	370.05	-	-	-	-	-	-	-
Inventory	597M	445M	445M	0	0	0	0	0	0	0
Days Inventory Outstanding	107.45	71.21	55.4	-	-	-	-	-	-	-
Other Current Assets	341M	250M	169M	0	0	0	0	9.58M	6.28M	17.01M
Total Non-Current Assets+	9.59B	10.07B	10.25B	110K	1.68M	4.25M	43.27M	40.73M	35.71M	31.95M
Property, Plant & Equipment	8.35B	7.12B	8.88B	110K	1.49M	1.95M	40.96M	38.41M	33.39M	30.01M
Fixed Asset Turnover	0.10x	0.19x	0.06x	-	-	-	-	-	-	-
Goodwill	797M	799M	772M	0	0	0	0	0	0	0
Intangible Assets	102M	38M	25M	0	0	0	0	0	0	0
Long-Term Investments	18M	16M	26M	0	0	0	0	0	0	0
Other Non-Current Assets	330M	1.67B	-31M	0	191K	2.3M	2.31M	2.32M	2.31M	1.94M
Total Assets+	11.54B	13.05B	11.77B	8.27M	16.44M	353.33M	425.66M	306.32M	165.08M	691.23M
Asset Turnover	0.07x	0.10x	0.04x	-	-	-	-	-	-	-
Asset Growth %	0.03%	0.13%	-0.1%	-1%	0.99%	20.5%	0.2%	-0.28%	-0.46%	3.19%
Total Current Liabilities+	812M	916M	1.05B	711K	2.36M	10.97M	28.72M	28.09M	51.09M	42.26M
Accounts Payable	292M	332M	367M	518K	1.26M	3.44M	4.03M	5.26M	22.94M	6.56M
Days Payables Outstanding	52.55	53.13	45.69	7.88K	1.69K	1.79K	-	-	3.4K	1.07K
Short-Term Debt	83M	201M	105M	0	0	0	0	0	0	0
Deferred Revenue (Current)	1000K	1000K	1000K	0	0	0	0	0	0	0
Other Current Liabilities	408M	378M	570M	9K	562K	0	0	0	0	30.85M
Current Ratio	2.40x	3.26x	1.45x	11.47x	6.26x	31.83x	13.31x	9.46x	2.53x	15.60x
Quick Ratio	1.66x	2.78x	1.03x	11.47x	6.26x	31.83x	13.31x	9.46x	2.53x	15.60x
Cash Conversion Cycle	229.16	121.22	379.76	-	-	-	-	-	-	-
Total Non-Current Liabilities+	7.42B	8.95B	8.48B	12.44M	42K	0	28.74M	25.87M	22.7M	19.14M
Long-Term Debt	7.21B	8.78B	8.33B	3.38M	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	0	28.74M	25.87M	22.7M	19.14M
Deferred Tax Liabilities	29M	5M	7M	0	0	0	0	0	0	0
Other Non-Current Liabilities	183M	170M	146M	9.06M	42K	0	0	0	0	0
Total Liabilities	8.62B	11.01B	9.87B	13.15M	2.4M	10.97M	57.47M	53.96M	73.79M	61.4M
Total Debt+	7.29B	8.98B	8.43B	3.38M	0	0	32.64M	30.48M	27.41M	23.99M
Net Debt	6.78B	7.2B	8.07B	-4.75M	-14.63M	-300.85M	-168.19M	-141.66M	-94.21M	-411.46M
Debt / Equity	2.50x	4.40x	4.44x	-	-	-	0.09x	0.12x	0.30x	0.04x
Debt / EBITDA	10.75x	71.26x	18.53x	-	-	-	-	-	-	-
Net Debt / EBITDA	10.01x	57.17x	17.73x	-	-	-	-	-	-	-
Interest Coverage	0.12x	-1.02x	-0.67x	-959.00x	-	-148.10x	-	-58.61x	-	-
Total Equity+	2.92B	2.04B	1.9B	-4.88M	14.04M	342.37M	368.2M	252.36M	91.29M	629.84M
Equity Growth %	-0.03%	-0.3%	-0.07%	-1%	3.88%	23.39%	0.08%	-0.31%	-0.64%	5.9%
Book Value per Share	23.18	15.83	11.73	-0.47	0.31	7.24	7.23	4.86	1.53	6.69
Total Shareholders' Equity	2.92B	2.04B	1.9B	-4.88M	14.04M	342.37M	368.2M	252.36M	91.29M	629.84M
Common Stock	1M	1M	1M	1K	1K	5K	6K	6K	6K	10K
Retained Earnings	-686M	-1.93B	-1.85B	-4.89M	-19.75M	-79.18M	-228.47M	-396.57M	-632.51M	-949.93M
Treasury Stock	0	0	0	-7K	0	0	0	0	0	0
Accumulated OCI	19M	21M	32M	-24K	0	-27K	-269K	-571K	0	6K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	94M	676M	585M	-4.16M	-11.83M	-46.51M	-119.56M	-153.65M	-188.16M	-292.37M
Operating CF Margin %	0.11%	0.49%	1.16%	-	-	-	-	-	-	-
Operating CF Growth %	2.52%	6.19%	-0.13%	-1.01%	-1.84%	-2.93%	-1.57%	-0.29%	-0.22%	-0.55%
Net Income	50M	-1.24B	76M	-4.81M	-14.86M	-59.44M	-149.29M	-168.1M	-235.94M	-317.42M
Depreciation & Amortization	614M	766M	867M	24K	271K	700K	1.09M	1.68M	1.67M	-1.93M
Stock-Based Compensation	0	0	0	1K	26K	6.59M	17.54M	15.18M	19.97M	45.86M
Deferred Taxes	477M	45M	610M	0	0	12K	2.59M	0	0	0
Other Non-Cash Items	-215M	136M	584M	21K	1.32M	514K	-746K	2.97M	-173K	607K
Working Capital Changes	-860M	938M	-1.6B	601K	1.41M	5.11M	9.26M	-5.38M	26.31M	-19.49M
Change in Receivables	-64M	42M	-47M	0	0	0	0	0	0	0
Change in Inventory	-119M	154M	110M	0	0	0	0	0	0	0
Change in Payables	90M	84M	46M	635K	1.69M	8.57M	13.7M	-1.24M	22.97M	-8.96M
Cash from Investing+	-1.19B	-2.15B	-2.76B	-134K	-1.65M	-45.66M	-137.89M	87.2M	83.31M	-204.08M
Capital Expenditures	-275M	-326M	-224M	-134K	-1.65M	-1.16M	-3.62M	-3.07M	-729K	-2.38M
CapEx % of Revenue	0.33%	0.24%	0.44%	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	5.41B	-1.82B	784M	0	0	0	-8K	-34K	0	35K
Cash from Financing+	-265M	2.74B	-1.3B	12.42M	19.99M	380.69M	157.82M	37.39M	54.32M	809.89M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-265M	2.74B	-1.3B	5M	0	-420K	584K	529K	1.95M	36.84M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-181M	350M	361M	-4.3M	-13.48M	-47.67M	-123.18M	-156.71M	-188.89M	-294.75M
FCF Margin %	-0.21%	0.26%	0.71%	-	-	-	-	-	-	-
FCF Growth %	-1.92%	2.93%	0.03%	-1.01%	-2.14%	-2.54%	-1.58%	-0.27%	-0.21%	-0.56%
FCF per Share	-1.44	2.71	2.23	-0.42	-0.30	-1.01	-2.42	-3.02	-3.16	-3.13
FCF Conversion (FCF/Net Income)	1.88x	-0.55x	7.70x	0.87x	0.87x	0.79x	0.80x	0.91x	0.80x	0.92x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	1.68%	-49.97%	3.85%	-0.51%	-295.64%	-32.96%	-42.02%	-54.18%	-137.31%	-88.03%
Return on Invested Capital (ROIC)	0.53%	-5.07%	-3.22%	-0.07%	-	-214.99%	-93.17%	-82.53%	-337.02%	-239.41%
Gross Margin	-140.86%	-66.98%	-479.45%	-	-	-	-	-	-	-
Net Margin	5.94%	-90.78%	15.02%	-	-	-	-	-	-	-
Debt / Equity	2.50x	4.40x	4.44x	-	-	-	0.09x	0.12x	0.30x	0.04x
Interest Coverage	0.12x	-1.02x	-0.67x	-959.00x	-	-148.10x	-	-58.61x	-	-
FCF Conversion	1.88x	-0.55x	7.70x	0.87x	0.87x	0.79x	0.80x	0.91x	0.80x	0.92x
Revenue Growth	-42.56%	62.23%	-62.96%	-100%	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

Dyne Therapeutics, Inc. (DYN) grew revenue by 0.0% over the past year. Growth has been modest.

Dyne Therapeutics, Inc. (DYN) reported a net loss of $423.8M for fiscal year 2024.

Dividend & Returns

Dyne Therapeutics, Inc. (DYN) has a return on equity (ROE) of -88.0%. Negative ROE indicates the company is unprofitable.

Dyne Therapeutics, Inc. (DYN) had negative free cash flow of $397.0M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Dyne Therapeutics, Inc. (DYN) 10-Year Financial Performance & Capital Metrics

DYN • • Industrial / General

HealthcareBiotechnologyRare Genetic DiseasesGene Therapy & Rare Diseases

Revenue $0
EBITDA -$342M -42.5%
Net Income -$317M -34.5%
EPS (Diluted) -3.37 +14.7%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -88.03% +35.9%
ROIC -239.41% +29.0%
Debt/Equity 0.04 -87.3%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Momentum leader: RS Rating 84 (top 16%)

✗Weaknesses

✗Shares diluted 57.7% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-43.9%

EPS CAGR

10Y-

5Y-

3Y-

TTM-2.81%

ROCE

10Y Avg-47.43%

5Y Avg-67.55%

3Y Avg-88.09%

Latest-90.14%

Peer Comparison

Gene Therapy & Rare Diseases

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
KRYSKrystal Biotech, Inc.	8.46B	291.79	97.26	473.02%	53.3%	17.48%	1.41%	0.01
BMRNBioMarin Pharmaceutical Inc.	10.77B	56.08	25.38	17.97%	16.82%	8.59%	4.41%	0.11
SRPTSarepta Therapeutics, Inc.	2.39B	22.80	9.74	52.97%	-11.25%	-20.57%		0.88
RAREUltragenyx Pharmaceutical Inc.	2.32B	24.07	-3.83	29.01%	-91.95%	-35.88%		0.15
DYNDyne Therapeutics, Inc.	2.87B	17.45	-5.18			-61.26%		0.04
TVTXTravere Therapeutics, Inc.	2.59B	28.93	-7.09	60.55%	-20.32%	-120.36%		6.80
BEAMBeam Therapeutics Inc.	3.59B	35.41	-7.73	-83.18%	-7.44%	-42.92%		0.22
SLNOSoleno Therapeutics, Inc.	2.28B	42.46	-9.69		-79.5%	-15.85%		0.22

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	842M	1.37B	506M	0	0	0	0	0	0	0
Revenue Growth %	-0.43%	0.62%	-0.63%	-1%	-	-	-	-	-	-
Cost of Goods Sold+	2.03B	2.28B	2.93B	24K	271K	700K	0	0	2.46M	2.24M
COGS % of Revenue	2.41%	1.67%	5.79%	-	-	-	-	-	-	-
Gross Profit+	-1.19B	-915M	-2.43B	-24K	-271K	-700K	0	0	-2.46M	-2.24M
Gross Margin %	-1.41%	-0.67%	-4.79%	-	-	-	-	-	-	-
Gross Profit Growth %	-4.69%	0.23%	-1.65%	1%	-10.29%	-1.58%	1%	-	-	0.09%
Operating Expenses+	128M	161M	189M	4.79M	13.83M	57.95M	150.03M	170.96M	239.7M	341.64M
OpEx % of Revenue	0.15%	0.12%	0.37%	-	-	-	-	-	-	-
Selling, General & Admin	128M	161M	189M	517K	2.79M	12.75M	28.72M	28.2M	31.4M	62.48M
SG&A % of Revenue	0.15%	0.12%	0.37%	-	-	-	-	-	-	-
Research & Development	0	0	0	4.28M	11.04M	45.2M	121.31M	142.76M	210.76M	281.41M
R&D % of Revenue	-	-	-	-	-	-	-	-	-	-
Other Operating Expenses	0	0	0	-21K	0	0	0	0	-2.46M	-2.24M
Operating Income+	64M	-640M	-412M	-4.79M	-13.83M	-58.65M	-150.03M	-170.96M	-242.16M	-343.89M
Operating Margin %	0.08%	-0.47%	-0.81%	-	-	-	-	-	-	-
Operating Income Growth %	1.2%	-11%	0.36%	0.99%	-1.88%	-3.24%	-1.56%	-0.14%	-0.42%	-0.42%
EBITDA+	678M	126M	455M	-4.77M	-13.55M	-57.95M	-148.94M	-169.28M	-239.7M	-341.64M
EBITDA Margin %	0.81%	0.09%	0.9%	-	-	-	-	-	-	-
EBITDA Growth %	27.08%	-0.81%	2.61%	-1.01%	-1.84%	-3.27%	-1.57%	-0.14%	-0.42%	-0.43%
D&A (Non-Cash Add-back)	614M	766M	867M	24K	271K	700K	1.09M	1.68M	2.46M	2.24M
EBIT	119M	-664M	78M	-4.81M	-14.86M	-59.04M	-150.03M	-170.96M	-235.94M	-317.42M
Net Interest Income+	0	0	0	0	290K	-340K	742K	0	7.64M	26.92M
Interest Income	0	0	0	5K	290K	56K	742K	2.92M	7.64M	26.92M
Interest Expense	546M	625M	616M	5K	0	396K	0	2.92M	0	0
Other Income/Expense	-491M	-649M	-126M	-16K	-1.03M	-790K	734K	2.86M	6.22M	26.47M
Pretax Income+	-427M	-1.29B	-538M	-4.81M	-14.86M	-59.44M	-149.29M	-168.1M	-235.94M	-317.42M
Pretax Margin %	-0.51%	-0.94%	-1.06%	-	-	-	-	-	-	-
Income Tax+	-474M	-45M	-610M	-11K	0	-700K	0	0	0	0
Effective Tax Rate %	-0.12%	0.96%	-0.14%	1%	0.91%	0.99%	1%	1%	1%	1%
Net Income+	50M	-1.24B	76M	-4.81M	-13.54M	-58.74M	-149.29M	-168.1M	-235.94M	-317.42M
Net Margin %	0.06%	-0.91%	0.15%	-	-	-	-	-	-	-
Net Income Growth %	1.75%	-25.8%	1.06%	-1.06%	-1.81%	-3.34%	-1.54%	-0.13%	-0.4%	-0.35%
Net Income (Continuing)	50M	-1.24B	76M	-4.81M	-14.86M	-58.74M	-149.29M	-168.1M	-235.94M	-317.42M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	0.40	-9.61	0.47	-0.47	-0.30	-1.24	-2.93	-3.23	-3.95	-3.37
EPS Growth %	1.75%	-25.02%	1.05%	-2%	0.36%	-3.13%	-1.36%	-0.1%	-0.22%	0.15%
EPS (Basic)	0.40	-9.61	0.47	-0.47	-0.30	-1.24	-2.93	-3.23	-3.95	-3.37
Diluted Shares Outstanding	126M	129M	162M	10.32M	45.42M	47.27M	50.9M	51.98M	59.68M	94.14M
Basic Shares Outstanding	125M	129M	162M	10.32M	45.42M	47.27M	50.9M	51.98M	59.68M	94.14M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	1.95B	2.99B	1.52B	8.16M	14.76M	349.09M	382.39M	265.59M	129.38M	659.28M
Cash & Short-Term Investments	605M	1.91B	397M	8.12M	14.63M	345.31M	376.57M	256.01M	123.1M	642.27M
Cash Only	505M	1.78B	365M	8.12M	14.63M	300.85M	200.82M	172.15M	121.63M	435.45M
Short-Term Investments	100M	130M	32M	0	0	44.46M	175.75M	83.86M	1.47M	206.82M
Accounts Receivable	402M	386M	513M	0	0	0	0	0	0	0
Days Sales Outstanding	174.26	103.14	370.05	-	-	-	-	-	-	-
Inventory	597M	445M	445M	0	0	0	0	0	0	0
Days Inventory Outstanding	107.45	71.21	55.4	-	-	-	-	-	-	-
Other Current Assets	341M	250M	169M	0	0	0	0	9.58M	6.28M	17.01M
Total Non-Current Assets+	9.59B	10.07B	10.25B	110K	1.68M	4.25M	43.27M	40.73M	35.71M	31.95M
Property, Plant & Equipment	8.35B	7.12B	8.88B	110K	1.49M	1.95M	40.96M	38.41M	33.39M	30.01M
Fixed Asset Turnover	0.10x	0.19x	0.06x	-	-	-	-	-	-	-
Goodwill	797M	799M	772M	0	0	0	0	0	0	0
Intangible Assets	102M	38M	25M	0	0	0	0	0	0	0
Long-Term Investments	18M	16M	26M	0	0	0	0	0	0	0
Other Non-Current Assets	330M	1.67B	-31M	0	191K	2.3M	2.31M	2.32M	2.31M	1.94M
Total Assets+	11.54B	13.05B	11.77B	8.27M	16.44M	353.33M	425.66M	306.32M	165.08M	691.23M
Asset Turnover	0.07x	0.10x	0.04x	-	-	-	-	-	-	-
Asset Growth %	0.03%	0.13%	-0.1%	-1%	0.99%	20.5%	0.2%	-0.28%	-0.46%	3.19%
Total Current Liabilities+	812M	916M	1.05B	711K	2.36M	10.97M	28.72M	28.09M	51.09M	42.26M
Accounts Payable	292M	332M	367M	518K	1.26M	3.44M	4.03M	5.26M	22.94M	6.56M
Days Payables Outstanding	52.55	53.13	45.69	7.88K	1.69K	1.79K	-	-	3.4K	1.07K
Short-Term Debt	83M	201M	105M	0	0	0	0	0	0	0
Deferred Revenue (Current)	1000K	1000K	1000K	0	0	0	0	0	0	0
Other Current Liabilities	408M	378M	570M	9K	562K	0	0	0	0	30.85M
Current Ratio	2.40x	3.26x	1.45x	11.47x	6.26x	31.83x	13.31x	9.46x	2.53x	15.60x
Quick Ratio	1.66x	2.78x	1.03x	11.47x	6.26x	31.83x	13.31x	9.46x	2.53x	15.60x
Cash Conversion Cycle	229.16	121.22	379.76	-	-	-	-	-	-	-
Total Non-Current Liabilities+	7.42B	8.95B	8.48B	12.44M	42K	0	28.74M	25.87M	22.7M	19.14M
Long-Term Debt	7.21B	8.78B	8.33B	3.38M	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	0	28.74M	25.87M	22.7M	19.14M
Deferred Tax Liabilities	29M	5M	7M	0	0	0	0	0	0	0
Other Non-Current Liabilities	183M	170M	146M	9.06M	42K	0	0	0	0	0
Total Liabilities	8.62B	11.01B	9.87B	13.15M	2.4M	10.97M	57.47M	53.96M	73.79M	61.4M
Total Debt+	7.29B	8.98B	8.43B	3.38M	0	0	32.64M	30.48M	27.41M	23.99M
Net Debt	6.78B	7.2B	8.07B	-4.75M	-14.63M	-300.85M	-168.19M	-141.66M	-94.21M	-411.46M
Debt / Equity	2.50x	4.40x	4.44x	-	-	-	0.09x	0.12x	0.30x	0.04x
Debt / EBITDA	10.75x	71.26x	18.53x	-	-	-	-	-	-	-
Net Debt / EBITDA	10.01x	57.17x	17.73x	-	-	-	-	-	-	-
Interest Coverage	0.12x	-1.02x	-0.67x	-959.00x	-	-148.10x	-	-58.61x	-	-
Total Equity+	2.92B	2.04B	1.9B	-4.88M	14.04M	342.37M	368.2M	252.36M	91.29M	629.84M
Equity Growth %	-0.03%	-0.3%	-0.07%	-1%	3.88%	23.39%	0.08%	-0.31%	-0.64%	5.9%
Book Value per Share	23.18	15.83	11.73	-0.47	0.31	7.24	7.23	4.86	1.53	6.69
Total Shareholders' Equity	2.92B	2.04B	1.9B	-4.88M	14.04M	342.37M	368.2M	252.36M	91.29M	629.84M
Common Stock	1M	1M	1M	1K	1K	5K	6K	6K	6K	10K
Retained Earnings	-686M	-1.93B	-1.85B	-4.89M	-19.75M	-79.18M	-228.47M	-396.57M	-632.51M	-949.93M
Treasury Stock	0	0	0	-7K	0	0	0	0	0	0
Accumulated OCI	19M	21M	32M	-24K	0	-27K	-269K	-571K	0	6K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	94M	676M	585M	-4.16M	-11.83M	-46.51M	-119.56M	-153.65M	-188.16M	-292.37M
Operating CF Margin %	0.11%	0.49%	1.16%	-	-	-	-	-	-	-
Operating CF Growth %	2.52%	6.19%	-0.13%	-1.01%	-1.84%	-2.93%	-1.57%	-0.29%	-0.22%	-0.55%
Net Income	50M	-1.24B	76M	-4.81M	-14.86M	-59.44M	-149.29M	-168.1M	-235.94M	-317.42M
Depreciation & Amortization	614M	766M	867M	24K	271K	700K	1.09M	1.68M	1.67M	-1.93M
Stock-Based Compensation	0	0	0	1K	26K	6.59M	17.54M	15.18M	19.97M	45.86M
Deferred Taxes	477M	45M	610M	0	0	12K	2.59M	0	0	0
Other Non-Cash Items	-215M	136M	584M	21K	1.32M	514K	-746K	2.97M	-173K	607K
Working Capital Changes	-860M	938M	-1.6B	601K	1.41M	5.11M	9.26M	-5.38M	26.31M	-19.49M
Change in Receivables	-64M	42M	-47M	0	0	0	0	0	0	0
Change in Inventory	-119M	154M	110M	0	0	0	0	0	0	0
Change in Payables	90M	84M	46M	635K	1.69M	8.57M	13.7M	-1.24M	22.97M	-8.96M
Cash from Investing+	-1.19B	-2.15B	-2.76B	-134K	-1.65M	-45.66M	-137.89M	87.2M	83.31M	-204.08M
Capital Expenditures	-275M	-326M	-224M	-134K	-1.65M	-1.16M	-3.62M	-3.07M	-729K	-2.38M
CapEx % of Revenue	0.33%	0.24%	0.44%	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	5.41B	-1.82B	784M	0	0	0	-8K	-34K	0	35K
Cash from Financing+	-265M	2.74B	-1.3B	12.42M	19.99M	380.69M	157.82M	37.39M	54.32M	809.89M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-265M	2.74B	-1.3B	5M	0	-420K	584K	529K	1.95M	36.84M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-181M	350M	361M	-4.3M	-13.48M	-47.67M	-123.18M	-156.71M	-188.89M	-294.75M
FCF Margin %	-0.21%	0.26%	0.71%	-	-	-	-	-	-	-
FCF Growth %	-1.92%	2.93%	0.03%	-1.01%	-2.14%	-2.54%	-1.58%	-0.27%	-0.21%	-0.56%
FCF per Share	-1.44	2.71	2.23	-0.42	-0.30	-1.01	-2.42	-3.02	-3.16	-3.13
FCF Conversion (FCF/Net Income)	1.88x	-0.55x	7.70x	0.87x	0.87x	0.79x	0.80x	0.91x	0.80x	0.92x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	1.68%	-49.97%	3.85%	-0.51%	-295.64%	-32.96%	-42.02%	-54.18%	-137.31%	-88.03%
Return on Invested Capital (ROIC)	0.53%	-5.07%	-3.22%	-0.07%	-	-214.99%	-93.17%	-82.53%	-337.02%	-239.41%
Gross Margin	-140.86%	-66.98%	-479.45%	-	-	-	-	-	-	-
Net Margin	5.94%	-90.78%	15.02%	-	-	-	-	-	-	-
Debt / Equity	2.50x	4.40x	4.44x	-	-	-	0.09x	0.12x	0.30x	0.04x
Interest Coverage	0.12x	-1.02x	-0.67x	-959.00x	-	-148.10x	-	-58.61x	-	-
FCF Conversion	1.88x	-0.55x	7.70x	0.87x	0.87x	0.79x	0.80x	0.91x	0.80x	0.92x
Revenue Growth	-42.56%	62.23%	-62.96%	-100%	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

Dyne Therapeutics, Inc. (DYN) grew revenue by 0.0% over the past year. Growth has been modest.

Dyne Therapeutics, Inc. (DYN) reported a net loss of $423.8M for fiscal year 2024.

Dividend & Returns

Dyne Therapeutics, Inc. (DYN) has a return on equity (ROE) of -88.0%. Negative ROE indicates the company is unprofitable.

Dyne Therapeutics, Inc. (DYN) had negative free cash flow of $397.0M in fiscal year 2024, likely due to heavy capital investments.